USE OF N1,N4-BIS[3-(ETHYLAMINO)PROPYL]-2-BUTENE-1,4-DIAMINE COMPOUNDS IN COMBINATION WITH EPIGENETIC-ACTING PHARMACEUTICALS FOR ENHANCED CANCER THERAPY

摘要

Combination methods for treatment of cancer and of blood disorders, using PG-11047 ((2Z)-Nl,N4-bis[3-(ethylamino)propyl]-2-butene-l,4-diamine) and PG-11048 ((2E)-N1,N4- bis[3-(ethylamino)propyl]-2-butene-l,4-diamine) in combination with DNA methyltransferase (DNMT) inhibitors, histone deacetylase (HDAC) inhibitors, or both DNA methyltransferase inhibitors and histone deacetylase inhibitors, are disclosed. Hematopoietic cancers, lung cancers, mesothelioma, cutaneous T-cell lymphoma (CTCL), multiple myeloma, solid tumors, and blood disorders such as myelodysplastic syndromes can be treated using the methods of the invention.